Bashar Fteiha
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Research Interests
Bashar Fteiha has a total of 52 co-authors. Here are the top co-authors by number of shared publications:
Eran Goldin
Hebrew Univ Jerusalem, Fac Med, Jerusalem, Israel
5 shared publicationsMahmud Mahamid
Hebrew Univ Jerusalem, Fac Med, Jerusalem, Israel
5 shared publicationsRamzi Kurd
Internal Medicine Department, Shaare Zedek Hospital, affiliated to the Hebrew University, Jerusalem
4 shared publicationsAlon Bnaya
The Adult Nephrology institute Shaare Zedek Medical Center School of Medicine Hebrew University Jerusalem Israel
3 shared publicationsAmir Orlev
Faculty of Medicine Hebrew University Jerusalem Israel
3 shared publicationsHani Karameh
Shaare Zedek Medical Center
3 shared publications
Latest Publications
- 2 July 2025
- Published by Elsevier in Transplantation Proceedings
- Vol. 57 (6) , 1071-1075
Precision Immunosuppression in a Carefully Selected Liver Transplant Population: Can MMF Alone “Hold the Fort “?
- 2 July 2025
- Published by Elsevier in Transplantation Proceedings
- Vol. 57 (6) , 1071-1075
Precision Immunosuppression in a Carefully Selected Liver Transplant Population: Can MMF Alone “Hold the Fort “?
- Open Access
- 12 December 2024
- Published by The Endocrine Society in JCEM Case Reports
- Vol. 3 (1) , luae235
Unusual Management of a Rare Case of Methimazole-Resistant Graves Disease
As the leading cause of hyperthyroidism, Graves disease (GD) does not often present with its classical triad of pretibial myxedema, goiter, and exophthalmos but instead is often recognized by various manifestations such as tachycardia, weight loss, jaundice, or dermatopathy and requires utmost clinical vigilance. Three treatment modalities for GD exist as antithyroid drugs (ATDs), radioactive iodine (RAI), and surgery, but each bears its own serious side effects. Furthermore, there have been several reports in the literature about ATD resistance that can complicate management. We describe a rare complex case of methimazole (MMI)-resistant GD in a 58-year-old woman with multiple comorbidities including heart failure, atrial fibrillation, liver cirrhosis, and hypertension. She presented with an initial complaint of diffuse swelling and was found to have severe thyrotoxicosis. Despite high doses of MMI, her thyroid function remained significantly elevated. Thyroid uptake and scan while on MMI showed high radioactive iodine uptake. After receiving RAI therapy, her thyroid function and bilirubin improved markedly, liver enzymes remained stable, and anasarca responded to diuretics. This case highlights the challenges in managing resistant GD and emphasizes the necessity of personalized treatment plans.
- 12 December 2024
- Published by The Endocrine Society in JCEM Case Reports
- Vol. 3 (1) , luae235
Open AccessUnusual Management of a Rare Case of Methimazole-Resistant Graves Disease
As the leading cause of hyperthyroidism, Graves disease (GD) does not often present with its classical triad of pretibial myxedema, goiter, and exophthalmos but instead is often recognized by various manifestations such as tachycardia, weight loss, jaundice, or dermatopathy and requires utmost clinical vigilance. Three treatment modalities for GD exist as antithyroid drugs (ATDs), radioactive iodine (RAI), and surgery, but each bears its own serious side effects. Furthermore, there have been several reports in the literature about ATD resistance that can complicate management. We describe a rare complex case of methimazole (MMI)-resistant GD in a 58-year-old woman with multiple comorbidities including heart failure, atrial fibrillation, liver cirrhosis, and hypertension. She presented with an initial complaint of diffuse swelling and was found to have severe thyrotoxicosis. Despite high doses of MMI, her thyroid function remained significantly elevated. Thyroid uptake and scan while on MMI showed high radioactive iodine uptake. After receiving RAI therapy, her thyroid function and bilirubin improved markedly, liver enzymes remained stable, and anasarca responded to diuretics. This case highlights the challenges in managing resistant GD and emphasizes the necessity of personalized treatment plans.
- 1 March 2023
- Vol. 25 (3) , 191-195
Nonalcoholic Fatty Liver Disease as a Risk Factor for Severe Cholangitis
Background: Nonalcoholic fatty liver disease (NAFLD) is one of the most prevalent chronic liver disorders. Acute cholangitis (AC) is a life-threatening illness.Objective: To determine whether NAFLD is a risk factor for the severity of AC.Methods: We retrospectively studied hospitalized patients with a diagnosis of AC over 5 years. Patients were divided into a NAFLD group and a non-NAFLD group. We compared the two groups with regard to demographic characteristics, co -morbidi-ties, laboratory data, and severity of AC (including Charlson Co -morbidity Index [CCI] and Tokyo Consensus meeting criteria).Results: In all, 298 of 419 hospitalized patients diagnosed with AC met the inclusion criteria. Of these, 73/298 (24.5%) were in the NAFLD group. NAFLD group patients were younger and more likely to be diabetic and obese than the non-NAFLD group. Participants in the NAFLD presented with higher serum C -reac-tive protein and higher liver enzymes (P < 0.05, for each param-eter) and with more events of organ dysfunction (P< 0.001) and bacteremia (P < 0.005). Regarding the severity of AC according to Tokyo Consensus, among the NAFLD group more patients presented with Grade II (39.7 vs. 33.3%, P < 0.001) and Grade III (23.3 vs. 18.3, P < 0.001) cholangitis. More Grade I cholan-gitis was found among the non-NAFLD group (48.4 vs. 37%, P < 0.001). Multivariate logistic regression analysis showed that NAFLD was independently associated with severe AC, Grade III (odds ratio 3.25, 95% confidence interval 1.65-6.45, P = 0.038).Conclusions: NAFLD is an independent risk factor for the se-verity of AC.
- 1 March 2023
- Vol. 25 (3) , 191-195
Nonalcoholic Fatty Liver Disease as a Risk Factor for Severe Cholangitis
Background: Nonalcoholic fatty liver disease (NAFLD) is one of the most prevalent chronic liver disorders. Acute cholangitis (AC) is a life-threatening illness.Objective: To determine whether NAFLD is a risk factor for the severity of AC.Methods: We retrospectively studied hospitalized patients with a diagnosis of AC over 5 years. Patients were divided into a NAFLD group and a non-NAFLD group. We compared the two groups with regard to demographic characteristics, co -morbidi-ties, laboratory data, and severity of AC (including Charlson Co -morbidity Index [CCI] and Tokyo Consensus meeting criteria).Results: In all, 298 of 419 hospitalized patients diagnosed with AC met the inclusion criteria. Of these, 73/298 (24.5%) were in the NAFLD group. NAFLD group patients were younger and more likely to be diabetic and obese than the non-NAFLD group. Participants in the NAFLD presented with higher serum C -reac-tive protein and higher liver enzymes (P < 0.05, for each param-eter) and with more events of organ dysfunction (P< 0.001) and bacteremia (P < 0.005). Regarding the severity of AC according to Tokyo Consensus, among the NAFLD group more patients presented with Grade II (39.7 vs. 33.3%, P < 0.001) and Grade III (23.3 vs. 18.3, P < 0.001) cholangitis. More Grade I cholan-gitis was found among the non-NAFLD group (48.4 vs. 37%, P < 0.001). Multivariate logistic regression analysis showed that NAFLD was independently associated with severe AC, Grade III (odds ratio 3.25, 95% confidence interval 1.65-6.45, P = 0.038).Conclusions: NAFLD is an independent risk factor for the se-verity of AC.
- Open Access
- 9 January 2023
- Published by Elsevier in Annals of Hepatology
- Vol. 28 (3) , 100897
Elevated lactate/albumin ratio as a novel predictor of in-hospital mortality in hospitalized cirrhotics
- 9 January 2023
- Published by Elsevier in Annals of Hepatology
- Vol. 28 (3) , 100897
Open AccessElevated lactate/albumin ratio as a novel predictor of in-hospital mortality in hospitalized cirrhotics
- 30 November 2022
- Published by Elsevier in Journal of Clinical and Experimental Hepatology
- Vol. 13 (2) , 218-224
Clinical Trajectory and Predictors of Intensive Care Unit Mortality Among Nonalcoholic Fatty Liver Disease Patients: A Retrospective Case–Control Study
- 30 November 2022
- Published by Elsevier in Journal of Clinical and Experimental Hepatology
- Vol. 13 (2) , 218-224
Clinical Trajectory and Predictors of Intensive Care Unit Mortality Among Nonalcoholic Fatty Liver Disease Patients: A Retrospective Case–Control Study
- 7 April 2021
- Published by American Society of Tropical Medicine and Hygiene in The American Journal of Tropical Medicine and Hygiene
- Vol. 104 (4) , 1596-1601
Morbidity among Arab–Israeli and Palestinian Hajj Pilgrims: A Prospective Study
Thousands of Palestinian and Arab–Israeli pilgrims travel to Mecca each year to complete their pilgrimage. To the best of our knowledge, no previous studies have characterized the infectious and noninfectious morbidity among Arab–Israeli or Palestinian Hajj pilgrims. Thus, we designed and conducted an observational questionnaire-based study to prospectively investigate the occurrence of health problems among these Hajjis who traveled to complete their Pilgrimage during 2019 Hajj season. For the purpose of the study, questionnaires were distributed to Hajj pilgrims at three different time occasions—before travel, inquiring on demographics and medical comorbidities; and 1 and 4 weeks after returning recording any health problems encountered during or after travel. Initial recruitment included 111 Hajjis. The mean age of responders was 49.5 (±9.1) years, with a Male:Female ratio of 1.3:1. The mean travel duration was 18.7 (13–36) days. Altogether, 66.3% of the pilgrims reported at least one health problem during and after the trip, of which 38.6% sought medical attention. Five (4.8%) hajjis were hospitalized, including life-threatening conditions. Cough was the most common complaint (53.8%), and 11.5% also reported fever. Pretravel counseling was associated with reduced outpatient and emergency room visits. We therefore concluded that a high rate of morbidity was reported among this cohort of Hajj pilgrims with a morbidity spectrum similar to pilgrims from other countries. Pretravel consultation with the purpose of educating the pilgrims on the health risks of Hajj may help reduce the morbidity for future Hajj seasons.
- 7 April 2021
- Published by American Society of Tropical Medicine and Hygiene in The American Journal of Tropical Medicine and Hygiene
- Vol. 104 (4) , 1596-1601
Morbidity among Arab–Israeli and Palestinian Hajj Pilgrims: A Prospective Study
Thousands of Palestinian and Arab–Israeli pilgrims travel to Mecca each year to complete their pilgrimage. To the best of our knowledge, no previous studies have characterized the infectious and noninfectious morbidity among Arab–Israeli or Palestinian Hajj pilgrims. Thus, we designed and conducted an observational questionnaire-based study to prospectively investigate the occurrence of health problems among these Hajjis who traveled to complete their Pilgrimage during 2019 Hajj season. For the purpose of the study, questionnaires were distributed to Hajj pilgrims at three different time occasions—before travel, inquiring on demographics and medical comorbidities; and 1 and 4 weeks after returning recording any health problems encountered during or after travel. Initial recruitment included 111 Hajjis. The mean age of responders was 49.5 (±9.1) years, with a Male:Female ratio of 1.3:1. The mean travel duration was 18.7 (13–36) days. Altogether, 66.3% of the pilgrims reported at least one health problem during and after the trip, of which 38.6% sought medical attention. Five (4.8%) hajjis were hospitalized, including life-threatening conditions. Cough was the most common complaint (53.8%), and 11.5% also reported fever. Pretravel counseling was associated with reduced outpatient and emergency room visits. We therefore concluded that a high rate of morbidity was reported among this cohort of Hajj pilgrims with a morbidity spectrum similar to pilgrims from other countries. Pretravel consultation with the purpose of educating the pilgrims on the health risks of Hajj may help reduce the morbidity for future Hajj seasons.
- 18 January 2021
- Published by Taylor & Francis in Scandinavian Journal of Gastroenterology
- Vol. 56 (3) , 369-373
Nonalcoholic fatty liver disease and the risk of post-endoscopic retrograde cholangiopancreatography pancreatitis: the hidden danger
Nonalcoholic fatty liver disease (NAFLD) has been identified as risk factor for several diseases; however, its association with post endoscopic retrograde cholangiopancreatography pancreatitis (PEP) has not been studied. To assess whether NAFLD is a risk factor for the development of PEP. We performed a retrospective multicenter study. All patients who underwent ERCP during 2013–2016 at either the Shaare Zedek Medical Center in Jerusalem or EMMS Nazareth hospital and who had a diagnosis of NAFLD by abdominal imaging were eligible for inclusion. Four hundred and one patients were included, among them, 38 (9.5%) were diagnosed with PEP according to clinical, laboratory and radiological criteria. In univariate analysis, the following risk factors were associated with increased risk for PEP; Fatty liver (OR 2.363, p = .01), elevated levels of aspartate transaminase (OR 1.008, p = .04), ALT (OR 0.979, p = .0007), alkaline phosphatase (OR 1.008, p = .01), gamma-glutamyl transferase (OR 1.014, p = .0005) and total bilirubin (OR 1.141, p = .005). In multivariate logistic regression analysis, only NAFLD showed statistically significant association with PEP (OR 3.224, 95% CI 1.548-6.713, p = .001) with receiver operator characteristics (ROC) area under the curve (AUC) of 0.8156. NAFLD was shown to be a risk factor for PEP. Therefore, we suggest considering prophylactic pancreatic stenting and/or NSAID’s suppositories among these patients.
- 18 January 2021
- Published by Taylor & Francis in Scandinavian Journal of Gastroenterology
- Vol. 56 (3) , 369-373
Nonalcoholic fatty liver disease and the risk of post-endoscopic retrograde cholangiopancreatography pancreatitis: the hidden danger
Nonalcoholic fatty liver disease (NAFLD) has been identified as risk factor for several diseases; however, its association with post endoscopic retrograde cholangiopancreatography pancreatitis (PEP) has not been studied. To assess whether NAFLD is a risk factor for the development of PEP. We performed a retrospective multicenter study. All patients who underwent ERCP during 2013–2016 at either the Shaare Zedek Medical Center in Jerusalem or EMMS Nazareth hospital and who had a diagnosis of NAFLD by abdominal imaging were eligible for inclusion. Four hundred and one patients were included, among them, 38 (9.5%) were diagnosed with PEP according to clinical, laboratory and radiological criteria. In univariate analysis, the following risk factors were associated with increased risk for PEP; Fatty liver (OR 2.363, p = .01), elevated levels of aspartate transaminase (OR 1.008, p = .04), ALT (OR 0.979, p = .0007), alkaline phosphatase (OR 1.008, p = .01), gamma-glutamyl transferase (OR 1.014, p = .0005) and total bilirubin (OR 1.141, p = .005). In multivariate logistic regression analysis, only NAFLD showed statistically significant association with PEP (OR 3.224, 95% CI 1.548-6.713, p = .001) with receiver operator characteristics (ROC) area under the curve (AUC) of 0.8156. NAFLD was shown to be a risk factor for PEP. Therefore, we suggest considering prophylactic pancreatic stenting and/or NSAID’s suppositories among these patients.
- Open Access
- 5 November 2020
- Published by Springer Nature in Research Square
Morbidity among Arab-Israeli and Palestinian Hajj Pilgrims - a Prospective study
Background – Thousands of Palestinian and Arab-Israeli pilgrims travel to Mecca each year to complete their pilgrimage. We prospectively investigated the occurrence of healthproblems among these Hajjis who travelled to complete their Pilgrimage during 2019 Hajj season.Methods - A prospective observational questionnaire-based study, distributed to Hajj pilgrims at 3 occasions - before travel, inquiring on demographics, and medical comorbidities; 1 and 4 weeks after returning recording any health problem during or after travel.Results – Initial recruitment included 111 Hajjis. The mean age of responders was 49.5 (+9.137) years with a M:F ratio of 1.3:1. Mean travel-duration was 18.7 days (13-36d). Altogether, 66.3% of the pilgrims reported at least one health problem during and after the trip, of which 38.6% sought medical attention. Five (4.8%) hajjis were hospitalized including life-threatening conditions. Cough was the most common complaint (53.8%), 11.5% also reported fever. Pre-travel counselling was associated with reduced outpatient and Emergency Room visits.Conclusion - A high rate of morbidity was reported among this cohort of Hajj pilgrims with a morbidity spectrum similar to pilgrims from other countries. Pre-travel consultation with the purpose of educating on the health risks of Hajj may help reduce the morbidity for future Hajj seasons.
- 5 November 2020
- Published by Springer Nature in Research Square
Open AccessMorbidity among Arab-Israeli and Palestinian Hajj Pilgrims - a Prospective study
Background – Thousands of Palestinian and Arab-Israeli pilgrims travel to Mecca each year to complete their pilgrimage. We prospectively investigated the occurrence of healthproblems among these Hajjis who travelled to complete their Pilgrimage during 2019 Hajj season.Methods - A prospective observational questionnaire-based study, distributed to Hajj pilgrims at 3 occasions - before travel, inquiring on demographics, and medical comorbidities; 1 and 4 weeks after returning recording any health problem during or after travel.Results – Initial recruitment included 111 Hajjis. The mean age of responders was 49.5 (+9.137) years with a M:F ratio of 1.3:1. Mean travel-duration was 18.7 days (13-36d). Altogether, 66.3% of the pilgrims reported at least one health problem during and after the trip, of which 38.6% sought medical attention. Five (4.8%) hajjis were hospitalized including life-threatening conditions. Cough was the most common complaint (53.8%), 11.5% also reported fever. Pre-travel counselling was associated with reduced outpatient and Emergency Room visits.Conclusion - A high rate of morbidity was reported among this cohort of Hajj pilgrims with a morbidity spectrum similar to pilgrims from other countries. Pre-travel consultation with the purpose of educating on the health risks of Hajj may help reduce the morbidity for future Hajj seasons.
- Open Access
- 30 October 2020
- Published by Wiley in International Journal Of Clinical Practice
- Vol. 75 (4) , e13788
Cardiac arrhythmias amongst hospitalised Coronavirus 2019 (COVID‐19) patients: Prevalence, characterisation, and clinical algorithm to classify arrhythmic risk
Objectives A significant proportion of COVID‐19 patients may have cardiac involvement including arrhythmias. Although arrhythmia characterization and possible predictors were previously reported, there are conflicting data regarding the exact prevalence of arrhythmias. Clinically applicable algorithms to classify COVID patients' arrhythmic risk are still lacking, and are the aim of our study. Methods We describe a single center cohort of hospitalized patients with a positive nasopharyngeal swab for COVID‐19 during the initial Israeli outbreak between 1/2/2020 –30/5/2020. The study's outcome was any documented arrhythmia during hospitalization, based on daily physical examination, routine ECG's, periodic 24‐hour Holter, and continuous monitoring. Multivariate analysis was used to find predictors for new arrhythmias and create classification trees for discriminating patients with high and low arrhythmic risk. Results Out of 390 COVID‐19 patients included, 28 (7.2%) had documented arrhythmias during hospitalization, including: 23 atrial tachyarrhythmias, combined atrial fibrillation (AF) and ventricular fibrillation, ventricular tachycardia storm, and 3 bradyarrhythmias. Only 7/28 patients had previous arrhythmias. Our study showed significant correlation between disease severity and arrhythmia prevalence (p<0.001) with a low arrhythmic prevalence among mild disease patients (2%). Multivariate analysis revealed background heart failure (CHF) and disease severity are independently associated with overall arrhythmia while age, CHF, disease severity, and arrhythmic symptoms are associated with tachyarrhythmias. A novel decision tree using age, disease severity, CHF, and troponin levels was created to stratify patients into high and low risk for developing arrhythmia. Conclusions Dominant arrhythmia among COVID‐19 patients is AF. Arrhythmia prevalence is associated with age, disease severity, CHF, and troponin levels. A novel simple Classification tree, based on these parameters, can discriminate between high and low arrhythmic risk patients.
- 30 October 2020
- Published by Wiley in International Journal Of Clinical Practice
- Vol. 75 (4) , e13788
Open AccessCardiac arrhythmias amongst hospitalised Coronavirus 2019 (COVID‐19) patients: Prevalence, characterisation, and clinical algorithm to classify arrhythmic risk
Objectives A significant proportion of COVID‐19 patients may have cardiac involvement including arrhythmias. Although arrhythmia characterization and possible predictors were previously reported, there are conflicting data regarding the exact prevalence of arrhythmias. Clinically applicable algorithms to classify COVID patients' arrhythmic risk are still lacking, and are the aim of our study. Methods We describe a single center cohort of hospitalized patients with a positive nasopharyngeal swab for COVID‐19 during the initial Israeli outbreak between 1/2/2020 –30/5/2020. The study's outcome was any documented arrhythmia during hospitalization, based on daily physical examination, routine ECG's, periodic 24‐hour Holter, and continuous monitoring. Multivariate analysis was used to find predictors for new arrhythmias and create classification trees for discriminating patients with high and low arrhythmic risk. Results Out of 390 COVID‐19 patients included, 28 (7.2%) had documented arrhythmias during hospitalization, including: 23 atrial tachyarrhythmias, combined atrial fibrillation (AF) and ventricular fibrillation, ventricular tachycardia storm, and 3 bradyarrhythmias. Only 7/28 patients had previous arrhythmias. Our study showed significant correlation between disease severity and arrhythmia prevalence (p<0.001) with a low arrhythmic prevalence among mild disease patients (2%). Multivariate analysis revealed background heart failure (CHF) and disease severity are independently associated with overall arrhythmia while age, CHF, disease severity, and arrhythmic symptoms are associated with tachyarrhythmias. A novel decision tree using age, disease severity, CHF, and troponin levels was created to stratify patients into high and low risk for developing arrhythmia. Conclusions Dominant arrhythmia among COVID‐19 patients is AF. Arrhythmia prevalence is associated with age, disease severity, CHF, and troponin levels. A novel simple Classification tree, based on these parameters, can discriminate between high and low arrhythmic risk patients.
- Open Access
- 29 October 2020
- Published by Wiley
Abnormal Baseline liver function tests are associated with death or mechanical ventilation in COVID-19
Background – Studies investigating the relation between baseline liver abnormality and COVID-19 patients’ outcomes during hospitalization are scarce. The aim of the study is to address and characterize this clinically important association. Methods – Retrospective single-center study of adults hospitalized with COVID-19 infection for whom the baseline liver function tests up to one year prior to the admission were available. The study cohort included hospitalized patients from COVID-19 wards and specialized COVID-19 intensive care unit. Subjects were divided into a normal and abnormal baseline LFT groups that were then compared with respect to demographic characteristics, co-morbidities and patients’ outcomes during hospitalization. Results – 133 of 444 subjects met the inclusion criteria and were included in the study. Of them, 50/133 (37.6%) had abnormal baseline LFTs. The mean age of the cohort subjects was 65.7 ± 22.1 years and the mean BMI was 28.7 ± 13.0. Subjects with abnormal LFTs were more likely to die (22% versus 4.8%, p = 0.004) or require mechanical ventilation (16% versus 4.8%, p = 0.03) during hospitalization when compared to their normal LFT counterparts. Multivariate analysis revealed that abnormal baseline LFT (OR 6, 95% CI 2.0 – 18.4) was the strongest predictor of death or requiring mechanical ventilation followed by diabetes mellitus (OR 4.5, 95% CI 1.3 – 14.8) and congestive heart failure (OR 3.9, 95% CI 1.2 – 12.5). Conclusion - patients known to have a baseline LFTs abnormality appear to be at an increased risk for death or mechanical ventilation during hospitalization with COVID-19.
- 29 October 2020
- Published by Wiley
Open AccessAbnormal Baseline liver function tests are associated with death or mechanical ventilation in COVID-19
Background – Studies investigating the relation between baseline liver abnormality and COVID-19 patients’ outcomes during hospitalization are scarce. The aim of the study is to address and characterize this clinically important association. Methods – Retrospective single-center study of adults hospitalized with COVID-19 infection for whom the baseline liver function tests up to one year prior to the admission were available. The study cohort included hospitalized patients from COVID-19 wards and specialized COVID-19 intensive care unit. Subjects were divided into a normal and abnormal baseline LFT groups that were then compared with respect to demographic characteristics, co-morbidities and patients’ outcomes during hospitalization. Results – 133 of 444 subjects met the inclusion criteria and were included in the study. Of them, 50/133 (37.6%) had abnormal baseline LFTs. The mean age of the cohort subjects was 65.7 ± 22.1 years and the mean BMI was 28.7 ± 13.0. Subjects with abnormal LFTs were more likely to die (22% versus 4.8%, p = 0.004) or require mechanical ventilation (16% versus 4.8%, p = 0.03) during hospitalization when compared to their normal LFT counterparts. Multivariate analysis revealed that abnormal baseline LFT (OR 6, 95% CI 2.0 – 18.4) was the strongest predictor of death or requiring mechanical ventilation followed by diabetes mellitus (OR 4.5, 95% CI 1.3 – 14.8) and congestive heart failure (OR 3.9, 95% CI 1.2 – 12.5). Conclusion - patients known to have a baseline LFTs abnormality appear to be at an increased risk for death or mechanical ventilation during hospitalization with COVID-19.